As physicians and researchers question whether certain treatments for early signs of breast cancer are necessary, the first large US study will seek to determine the best way to manage ductal carcinoma in situ.
Later this year, the first large US study seeking to find the best way to treat an early sign of breast cancer will be launched under the direction of E. Shelley Hwang, MD, chief of breast surgery at the Duke Cancer Institute. She will lead the study, Comparison of Operative to Medical Endocrine Therapy (COMET), through the cooperative Alliance for Clinical Trials in Oncology. COMET will study ductal carcinoma in situ (DCIS), which is a small cluster of abnormal cells in the breast ducts that has not spread to surrounding tissue.
DCIS is currently diagnosed annually in about 60,000 women in the United States and is treated similarly to more advanced breast cancers with surgery and radiation therapy. Physicians and researchers have questioned whether those treatments are necessary in all cases given that DCIS lesions do not grow rapidly or spread in most women with the diagnosis. Treatment can cause side effects and lead to significant personal and societal costs. The study will show if actively monitoring many of these patients is a potentially alternative treatment.
Dr. Hwang, who has been a leading voice in the national debate calling for a more informed approach to DCIS treatment, expects the trial to help set the course for future DCIS treatment. She will work with Alastair M. Thompson, MD, from the University of Texas MD Anderson Cancer Center, and Ann H. Partridge, MD, from Dana-Farber Cancer Institute. The study will enroll 900 patients diagnosed with low-risk DCIS from 100 cancer centers through the United States. It will take 4 years to accrue all patients; follow-up and analysis will continue for at least 5 years. The study will provide data about the best candidates for active surveillance and create a repository of imaging and cell samples to advance knowledge into the molecular biology of DCIS and what fuels or slows its growth.
Women with DCIS who participate in the study will be randomized to receive one of two treatment approaches: the current standard-of-care of surgery and radiation therapy or careful monitoring with mammograms and physical exams every 6 months. Any patient whose DCIS progresses would be immediately treated with standard therapy.
The study was funded through a $13.4 million, 5-year award from the Patient-Centered Outcomes Research Institute, an independent, nonprofit organization authorized by Congress to support research enlightening health care decisions.
Persistence Pays Off With Zanubrutinib: A Challenging CLL Case With a Prior BTK Inhibitor Failure
May 10th 2024The case of a 77-year-old woman with a long chronic lymphocytic leukemia (CLL) history illustrates the novel use of zanubrutinib as a potential option for some patients who have failed first-generation Bruton tyrosine kinase (BTK) inhibitors and venetoclax.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Posters Characterize DMD Caregiver Experiences, Impact of Gene Therapy on Caregiving Demands
May 10th 2024Posters presented at the ISPOR—The Professional Society for Health Economics and Outcomes Research meeting explored Duchenne muscular dystrophy (DMD) caregiver experiences and gene therapy’s impact on work opportunities for caregivers.
Read More